Measurements of oxidative metabolic capacity following the ablation of rat sensorimotor cortex and the administration of amphetamine were examined to determine their effects on the metabolic dysfunction that follows brain injury. 
INTRODUCTION
Short term treatment(s) with D-amphetamine (AMPH), when administered late after a unilateral sensorimotor cortex ablation, embolic stroke, or traumatic brain injury (TBI) and combined with physical therapy (PT), results in an enduring acceleration of recovery from hemiplegia in rats and cats (Feeney et al., 1982; Hovda & Feeney, 1984; Sutton et al., 1987; Feeney & Westerberg, 1990; Feeney 1998a (Boyeson & Feeney, 1991) or the substantia nigra (Mintz & Toner, 1989) . In rats with unilateral sensorimotor cortex ablation, a single low dose of AMPH combined with PT, given one day after surgery, significantly enhances ftmctional recovery (Feeney et al., 1982; Goldstein, 1988; (Salo & Feeney, 1987; Hurwitz et al., 1991) . Cats with unilateral or bilateral frontal lobe ablation require three high doses of AMPH, beginning 10 days after injury, for drug-induced acceleration of beam-walking recovery to occur (Hovda & Feeney, 1984; Sutton et al., 1989b) . In a few clinical trials, this beneficial effect of treatment with AMPH + PT was extended to hemiplegic stroke patients, with preliminary work on aphasic stroke patients (Walker-Batson et al., 1992; 1995;  for review, see Goldstein, 1993; Feeney, 1997; 1998a; 1998b) . The recovery from hemiplegia of patients receiving short-term treatment with AMPH + PT, begun as long as 1 month after stroke, was significantly enhanced when compared with that of patients given placebo + PT. Significantly, this benficial effect of a 10-week treatment was enduring because it remained significant for months after discontinuing treatment for the 1-year period of study (Walker-Batson et al., 1995) . This opportunity to delay treatment for stroke or TBI is very important because it allows the physician time to make a full evaluation and to stabilize the patients before initiating therapy. Significantly, the vast majority of stroke patients do not seek medical attention within the first 3 to 6 hours after an infarct, when alternative treatments for stroke are most effective (Ginsberg & Pulsinelli, 1994) , and thus can suffer significant side effects (Bath, 1995) . Clearly (Feeney & Westerberg, 1990 ; Goldstein & Davis, 1990; Feeney, 1991; 1998a;  Boyeson & Harmon, 1993; Goldstein, 1993; Boyeson et al., 1994; Feeney et al., 1994) . In addition, intraventricular infusion of NA, but neither dopamine (Boyeson & Feeney, 1990) nor serotonin (Boyeson et al., 1994; Feeney, personal observations) , promotes recovery from hemiplegia after cortical injury. The requirement for PT during the period of drug action to optimize functional recovery after AMPH treatment suggests an interaction between two processes during this experimental treatment. As originally proposed and subsequently expanded (Feeney, 1998a; 1998b) , the two processes involve drug release of the neuromodulator NA which, by alleviating hypometabolic regions, "enables" PT to act upon intact but nonfunctional "performance" circuits that are normally involved in the behaviors that are lost after injury. These afferent inputs are thought to be both proprioceptive feedback and corollary discharges from the attempted movement. The mechanisms resulting from these processes are unknown, but several have been hypothesized, including (a) NA-induced unmasking or permitting the use of alternative pathways (Dietrich et al., 1990) , (b) enhancing attention by increasing the signalto-noise ratio of unit activity evoked during PT (Segal & Bloom, 1976a , 1976b Woodard et al., 1979; Robbins et al., 1985) , or (c) enhancing longterm potentiation as a model of plasticity (Gold et al., 1984) .
Our own research on the mechanisms of AMPH-induced functional recovery has focused on the ability of this treatment to alleviate an injury-induced metabolic depression in morphologically intact brain tissue, remote from the primary injury. The concept of remote functional depression, or diaschisis, following brain injury has a long history, but only recently have techniques been developed for measuring neuronal function. This evolving concept has been reviewed elsewhere (Feeney & Baron, 1986; Feeney, 1991) .
Studies reporting that injury to the cerebral cortex produces widespread alterations in both glycolytic (Pappius, 1981; Hosokawa et al., 1985; Gilman et al., 1987; Sutton et al., 1989a; Yoshino et al., 1991; Hovda et al., 1996;  Queen et al., 1997) and oxidative Hovda et al., 1991; Hovda & Villablanca, 1998) metabolism substantially support the concept of an injury-induced remote functional depression.
In a number of studies, functional recovery from injury-induced neurobehavioral deficits has been correlated with an alleviation of depressed cerebral metabolism (Colleet al., 1986; Gilman et al., 1987; Hovda et al., 1987; Hovda & Villablanca, 1990; Hovda, 1996) .
The concept that producing a functional depression and reduction of neuronal excitability contributes to the symptoms of brain injury is supported by the work of Brailowsky et al. (1986) . In his work, Dr. Brailowsky reported that the short-lasting hemiplegia induced by the insertion of saline-filled osmotic minipumps into the sensorimotor cortex of rats was potentiated when the minipumps were filled with GABA. In essence, this worsening of hemiplegia by GABA can be viewed as a drug-induced diaschisis or remote functional depression. Others have reported drug-induced remote functional depression (Khan et (Feeney, 1998a) .
Whereas all these post-injury events may produce diaschisis, none is essential.
Alleviation of remote metabolic depression after brain injury by drugs increasing cerebral NA has been reported in both the rat Feeney, 1991; 1998b; Hovda, 1996) and the cat (Hovda et al., 1987) . In rat studies addressing the metabolic depression that is associated with fluid percussion TBI, Hovda (1996) (Feeney et al., 1982; Hovda & Feeney, 1984; Goldstein & Davis, 1990) and for alleviating some visual deficits in cats following bilateral visual cortex ablation . A possibly related drug/ experience interaction has been described in a PET study of rCBF in normal human beings who were given a low dose of AMPH before performing different tasks (Mattay et al., 1996) . The (Hovda et al., 1987) . The effect of AMPH on oxidative capacity after sensorimotor cortex ablation has not yet been studied, however. Alteration of oxidative capacity after cortical trauma was studied using C.O. histochemistry (Weisend et al., 1990; Hovda et al., 1991) . Surgery and group assignments Animals were randomly assigned to sham injury (N=8) or to ablation (N=8) groups before surgery. After overnight fasting, the animals were anesthetized with ketamine hydrochloride (60 mg/kg, i.m.) followed by sodium pentobarbital (21 mg/kg, i.p.) and positioned in a stereotaxic frame. Animals assigned to injury groups had the right sensorimotor cortex ablated, as described previously (Feeney et al., 1982; As side was not treated as a withinsubject factor, the degrees of freedom were inflated. Given the a priori hypothesis of effects being more prevalent in the hemisphere ipsilateral to the lesion, however, we felt that these independent comparisons were warranted. Following the overall analysis incorporating a least-squares approach, we then made comparisons to determine the significance of the main effect (group), with simple main effects comparisons being made among groups using appropriate contrasts (Hays, 1973; Myers, 1979) .
RESULTS

Extent of injury and stain quality
In both SAL-and AMPH-treated groups, the cortical injuries were similar to those described previously (Ginsberg et al., 1977; Dail et al., 1981; Nemoto et al., 1981; Pappius, 1982; Pappius & Wolfe, 1983; Kushner et al., 1984; Dauth et al., 1985; Colle et al., 1986; Hovda et al., 1987; Kiyosawa et al., 1987; Lagreze et al., 1987; Beck et al., 1990; Fiorelli et al., 1991; Yoshino et al., 1991; To our knowledge, studies specifically addressing CBF following restricted ablation of the cortex have not yet been conducted. CBF has primarily been studied in models of cerebral ischemia (Pulsinelli et al., 1982; Raichle, 1983; Perani et al., 1987; LaManna et al., 1988; Vannucci et al., 1988; Bolander et al., 1989;  Dimagl & Pulsinelli, 1990; Ginsberg, 1990) and of experimental TBI (Lewelt et al., 1980; Dewitt et al., 1986; McIntosh et al., 1987; Unterberg et al., 1988; Yuan et al., 1988; Yamakami & Mclntosh, 1989; Shima & Marmarou, 1991; Muir et al., 1992) . In cases where CBF was not directly measured, the investigators measured ATP (MacMillan, 1982; Pulsinelli & Duffy, 1983; Fass et al., 1987; Komatsumoto et al., 1987) , protein synthesis (Lipton & Heimbaeh, 1977; Mies et al. 1991) , and extracellular lactate (Pulsinelli & Duffy, 1983; Prasad et (Hovda et al., 1987; Shaw et al., 1988; Jen et al., 1989; Chiaia et al., 1991; Hovda et al., 1991; Hovda & Villablanea, 1998) .
As the most efficient method of generating ATP, oxidative metabolism tends to run at a relatively constant optimal level (Aekermann & Lear, 1989; Barinaga, 1997) . With its rate of use dictated by the amount of cytoehrome e within the mitochondria, oxidative metabolism can only be upregulated above the maximal level via the manufacture of additional protein. Given that the production of protein can take anywhere from hours to days, cells must rely on a more rapid and dynamic process for satisfying the acute increases in energy demands that are associated with ionic pertubation and/or neuronal firing. It would appear that this quickly responsive process is glyeolysis, and this has been the basis for the concept of energy compartmentalization described in both cardiac and brain physiology. This is one of many reasons why, when measurements of glucose metabolism are conducted using 2-DG autoradiography, a physiological steady state must be maintained throughout the uptake period (Sokoloffet al., 1977) .
As has been described by many investigators who are interested in the recovery of function following brain injury, the very acute period after injury is often quite dynamic in terms of the energy demands being placed on cells, but the most pronounced feature in the chronic state is a widespread or generalized metabolic depression, as studied using several different techniques. A critical question is whether these longer, more chronic measures of metabolism following injury are simply an index for the current state of the animal over a period of minutes (when 2-DG techniques are used), or whether the overall set point of cerebral metabolism has been fundamentally changed Hovda & Villablanca, 1998) . In previous work on the pharmacology of recovery from brain injury, we took the position, along with others, that injury to the brain results in a pronounced chronic depression of function, reflected in measures of neurotransmitter levels (Krobert et al., 1994) , as well as in metabolism. Evidence that drugs enhancing post-injury behavioral recovery also alleviate injury-induced hypometabolism provides support for such concepts as remote functional depression or diaschisis Feeney and Sutton, 1987; Feeney, 1991) . In many cases, the metabolic depression that is induced by brain injury may diminish spontaneously, consistent with von Monakow's construct of diaschisis. Unfortunately, von Monakow gave this concept a circular definition, invoking the term diaschisis to explain the spontaneous remission of symptoms after injury. The measures of metabolic dysfunction provide an independent measure of the concept, eliminating his tautology. As demonstrated in the current paper, as well as in prior studies Hovda et al., 1987; Dietrich et al., 1990; Hovda, 1996; Queen et al., 1997) Feeney, 1997; 1998a; 1998b) (Goldstein, 1988; . Additionally, these drugs increase cerebral metabolism, as measured by PET-scan studies of rCBF (Schmidt et al., 1995; Bremner et al., 1997) . Significantly, similar to the interaction between AMPH and PT to promote recovery, no fixed action of AMPH on cerebral glucose utilization occurs, but rather the activated areas depend upon the task the subject is doing during the period of drug action (Mattay et al., 1996) . Whatever the mechanism, clearly an injury-induced metabolic depression is related to the degree and to the extent of recovery of function, given that recovery from deficits is closely correlated with the recovery to normal rates of cerebral metabolism (Hovda, 1996) . (Dehay & Kennedy, 1988; Hovda et al., 1992) , cerebral decortication (Hovda & Villablanca, 1998) , and the effects of sensory deprivation or stimulation (Kageyama & Wong-Riley, 1986; WongRiley & Norton, 1988; Wong-Riley, 1989) . As in the current study, previous investigators have used optical densitometry to assess C.O. activity in regions of the cerebrum (Darriet et al., 1986; Hovda et al., 1987 Hovda et al., , 1991 Hovda et al., , 1992 Kageyama & Meyer, 1988; Hovda & Villablanca, 1990 , 1998 Hyde & Dmimm, 1990 (Porrino et al., 1984) . Such an acute increase in ICMRglc after AMPH may be related to the rapid increase in NA that has been reported after drug treatment in rats (Krobert et al., 1994 ). In the current study, the lack of C.O. increase in normal rats given AMPH most likely reflects the fact that oxidative metabolism in normal animals runs at peak efficiency levels and, therefore, cannot be upregulated dynamically by a single injection of AMPH. The depression of C.O. observed in our study may be related to a "post-intoxication" effect of AMPH, reflecting the after effects of an initial global neural activation by this drug. In normal human subjects, AMPH was reported to slightly decrease 1CMRglc in cortical regions by 3 hours post-drug (Wolkin et al., 1987) . (Dail et al., 1981; Hovda et al., 1991; Hovda, 1996; ) and glycolytic (Pappius, 1981; Colleet al., 1986; Pappius et al., 1988; Sutton et al., 1989a; Dielrich et al., 1990; Yoshino et al., 1991; Queen et al., 1997) metabolism. As with the current findings, such injury-induced metabolic depressions are most evident within the ipsilateral cortical and/or subcortical regions during the first few days post injury. The physiological consequences of these injuryinduced metabolic depressions may be functionally related to the neurobehavioral deficits in the contralateral limbs that are exhibited during this same time period post injury (Feeney et al., 1982; Gilman et al., 1987; Sutton et al., 1987; .
AMPH-induced alleviation of metabolic depression may contribute to the ability of the drug to alleviate symptoms (Feeney, 1998b) , which has been extended to stroke patients (reviewed in Goldstein, 1993; Feeney, 1997) . This effect has also been demonstrated by Hovda and his colleagues (1996) , who showed that the AMPH-induced alleviation of metabolic depression following fluid percussion injury was directly related to an increased rate of behavioral recovery.
Prior research on cortical concussion injury Feeney 1998b) (Dietrich et al., 1990) . Most studies on the effect ofAMPH on functional recovery after unilateral cortex ablation have employed the beam-walking scale developed by Feeney and colleagues (Feeney et al., 1982; (Feeney, personal observation) , which may contribute to the inability of some rats to traverse the beam during the first few days after injury. Mild and transient deficits in the hindlimb ipsilateral to cortical contusion injury (specifically, delayed response times to retract the limb after lateral and posterior displacement (Sutton et al., 1990) , has also been observed. At present, we can only speculate that a bilateral decrease in oxidative capacity may contribute to these bilateral deficits, and that an AMPH-induced alleviation of this decreased oxidative metabolism may facilitate recovery in both the ipsilateral and the contralateral limbs. Firm conclusions will depend upon further studies employing both behavioral tasks that are sensitive to potential bilateral deficits and analyses of potential bilateral metabolic responses to injury and/or drug treatment.
In conclusion, this study has demonstrated that a single AMPH treatment attenuates the depression of the cerebral oxidative metabolism that occurs after unilateral sensorimotor cortex ablation. We previously reported that AMPH treatment attenuates the decrease in ICMRglc and the paling of alpha glycerophosphate dehydrogenase staining that occurs after sensorimotor cortex injury Queen et al., 1997) . Likewise, Dietrich et al. (1990) reported that AMPH treatment increases ICMRglc in cortical regions following photochemically induced cortical infarcts. These effects of AMPH on cerebral metabolism after cortical injury support a general hypothesis Hovda et al., 1987; Feeney, 1991; Feeney, 1998a Feeney, , 1998b ) that AMPH may exert its beneficial effects on behavioral recovery by alleviating a metabolic dysfunction (namely, a remote functional depression) that is induced by cortical injury.
